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Abstract
Human diseases caused by single-stranded, positive-sense RNA viruses, are 
among the deadliest of the 21st Century. In particular, there are two notable stand-
outs: human immunodeficiency virus (HIV) and severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Detection of these disease-causing viral transcripts, 
by next-generation RNA sequencing (RNA-Seq), represents the most immediate 
opportunity for advances in diagnostic, therapeutic, and preventive applicability in 
infectious diseases (e.g., AIDS and COVID-19). Moreover, RNA-Seq technologies 
add significant value to public health studies by first, providing real-time surveil-
lance of known viral strains, and second, by the augmentation of epidemiological 
databases, construction of annotations and classifications of novel sequence 
variants. This chapter intends to recapitulate the current knowledge of HIV and 
SARS-CoV-2 transcriptome architecture, pathogenicity, and some features of the 
host immune response. Additionally, it provides an overview of recent advances 
in diagnostic sequencing methodologies and discusses the future challenges and 
prospects on the utilization of RNA-Seq technologies.
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1. Introduction
Next-generation RNA sequencing is rapidly replacing cDNA microarrays and 
quantitative PCR in clinics and in the public health laboratories, due to higher 
sensitivity and precision, as well as its cost-effective ability to identify novel RNA 
species. High-throughput sequencing has become widely adopted in infectious 
diseases. Supporting bioinformatics services have improved substantially, which 
aids in genotyping causative mutations for antimicrobial resistance, pathogens’ 
virulence factors, and global epidemiological surveillance to monitor molecular 
dynamics of pathogen diversity [1, 2]. Integration of pathogen genome sequenc-
ing into infectious disease surveillance was established by United States Centers 
for Disease Control and Prevention (CDC) under Advanced Molecular Detection 
program in 2016 [2]. As described below, RNA sequencing became particularly 
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important to identify newly emerging HIV and SARS-CoV strains. RNA-Seq can 
be used for many different purposes, such as improve diagnostics, characterization 
of novel strains, investigation of disease epidemiology, spatiotemporal spread and 
transmission routes, assessment of evolutionary rates, and the development of 
countermeasures and public health policies.
The standard practice of viral RNA detection is composed of a two-step pro-
cedure - reverse transcription of RNA into cDNA and cDNA amplification. The 
reverse transcription reaction is prone to recombination errors leading to potential 
alterations in the amplicon library and inadequate sequence representation of the 
original sample. Although both the nucleic acid amplification test (NAAT) and real-
time reverse transcriptase - polymerase chain reaction (RT-PCR) test are cost-effec-
tive, the occurrence of amplicon failures needs to be monitored for substitutions 
in primer binding sites. In order to circumvent possible mutations in the primer 
regions, it is recommended multiple primer designs targeting the same genes, when 
designing RT-PCR assays [3, 4]. The RNA-Seq method is capable to unbiasedly 
identify variants across thousands of target regions with single-base resolution, in 
cases where NAAT or qRT-PCR produce false-negative results.
Illumina’s technology appears to be at the forefront of viral sequencing, however 
others such as IonTorrent and Oxford Nanopore technologies are quickly closing 
the gaps [5]. Illumina deploys sequencing-by-synthesis chemistry, which provides 
high accuracy and deep coverage of the viral genome. A limitation of Illumina is 
that short read length (< 400 nt) fragmented sequences should be re-assembled 
computationally, during which the haplotype information can be lost. Short-read 
sequencing data requires computational pipelines for trimming of low-quality 
reads, removal of optical duplicates, detection of reads orientation, and alignment 
to reconstruct full-length viral sequences. Short read RNA-Seq technologies allow to 
pull multiple samples per lane to reduce the cost, however, demultiplexing of reads 
from different samples can be bioinformatically challenging.
The recent shift toward emerging long-read technologies, enabled direct 
sequencing of individual RNA molecules as opposed to classical indirect approaches 
[6]. Long-read RNA-seq technologies, such as that provided by Ion Torrent or 
Oxford Nanopore, allow mapping of novel insertions, deletions, or substitutions 
in natural variants [7]. Thus, the technology offers advantages over established 
sequencing technologies, as it has simplified procedures for library preparation and 
bioinformatics analysis. Although direct RNA sequencing possesses low accuracy, 
than Illumina’s short read method, it enables easier full-length sequencing, rapid 
viral genome annotation and analysis, which would be particularly useful for 
understanding changes in transcriptome architectures [8]. Additionally, long-read 
technologies are more cost-effective, portable, and provide robust reproducibility 
of the results, when compared to short-read RNA-seq [9]. A heterozygous variants 
can be detected when filtered by bioinformatic pipelines, which may identify co- 
infections and estimate the risk of superinfection [10]. Detailed descriptions and of 
long- and short- read methodologies, as well as analysis workflows, are provided in 
other chapters of this book.
2. Sequencing of human immunodeficiency virus (HIV)
The human immunodeficiency virus (HIV) is organized in the genus Lentivirus, 
within the family of Retroviridae, subfamily Orthoretrovirinae. HIV is a human 
retrovirus with an RNA genome that is composed of copies of a single stranded 
positive sense RNA [11]. The RNA genome encodes viral enzymes and is packed 
into nucleocapsid proteins (the viral capsid). After infecting the cell, the viral RNA 
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genome is reverse transcribed into double stranded viral DNA, which is subse-
quently integrated into cellular host DNA with the aid of viral and host cofactors. 
The HIV life cycle has several life-cycle phases; a prolonged latent phase of host 
genome integration, and a phase of active transcription of new viral RNA in the 
infected cell [11]. The of HIV replication process is characterized by high rates of 
nucleotide misincorporations, insertions, deletions, and recombinations. Twentieth 
century research studies, in 1980s and 1990s, uncovered only a partial viral genome. 
Determination of the HIV partial genome sequence provided the basis for the 
development of next-generation sequencing and real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) methods.
Next-generation RNA-Sequencing enabled the first successful pan-HIV-1 
sequencing, including subtype identification and phylodynamic diversification dur-
ing the course of AIDS pandemic [12]. The current HIV nomenclature includes two 
types: HIV-1 and HIV-2. The HIV-1 is phylogenetically classified into of 4 groups (M, 
N, O, and P) [13]. Phylodynamic analyses and evolutionary clock models estimated 
the time of the most recent common ancestor (HIV-1 pandemic group) to be around 
the late 19th – early 20th centuries, in Central Africa, and where it may have been 
associated with an epidemic in primates [14]. The major (M) pandemic group, which 
causes human-to-human transmission, is classified into 9 subtypes. The most preva-
lent M subtypes are A, B, C, D, and G; while subtypes F, H, J, L and K are collectively 
responsible for approximately 1% of all HIV infections [14–16]. An important genetic 
feature of HIV is that it is prone to recombination. The highest levels of inter-subtype 
re-combinations are found in HIV-1 infected specimens, from patients in the Sub-
Saharan region of Africa. Analysis of a whole-genome HIV-1 sequence, from the 
Congo Basin, identified ancestral HIV species which clustered basal to all major 
subtypes; many of which underwent purifying selection and are no longer in circula-
tion. However, 72 additional recombinant forms of HIV remain in circulation [17].
Intra-individual mixtures of recombinant genomes have been reported 
throughout the world. It is hypothesized that inter-subtype recombinant viruses 
have an advantage of transmissibility over parental strains [18–24]. To achieve full 
viral genome sequence coverage, several approaches were employed. One such 
approach was the amplification of two large fragments (“half genomes”), span-
ning the full HIV-1 sequence, including all critical regions. Using this approach, 
molecular surveillance studies of circulating and recombinant forms of HIV, has 
been conducted in Cameron. Researchers used primers which target two overlap-
ping “half genome” sequencing approach: the 5′ region (gag and pol genes), the 3′ 
region (env and nef), which overlap the accessory genes (vif, vpr, and vpu) [25]. 
The two-amplicon approach followed by deep sequencing allowed to characterize 
several novel circulating recombinant forms, CRFs, (CRF02_AG, _AE, _01A1, and 
F2, CRF_36cpx and _37cpx, etc.) and more than a dozen unique recombinant forms 
(URF, NYU6541_6, NYU6556_3, etc.) that clustered separately from their reference 
sequences, as determined by the maximum likelihood phylogenetic algorithm [26]. 
The introduction of circulating recombinant forms (CRF01_AE and CRF02_AG) 
into the Asian-Pacific region from Continental Asia was identified using similar 
“half genome” sequencing approach [27]. Another approach, the “switching 
mechanism at the 5′ end of RNA transcript” (SMART), leverages the template-
switching capability of certain RT enzymes toward full-length template. During 
RT reaction, three additional nucleotides are added to the 3′ end of the first cDNA 
strand of viral RNA template, which serve as an anchor for selective amplification 
of full length template with a set of 5′ adaptor-ligated primer [28]. This method was 
adopted to capture full-length HIV sequence in clinical samples, in which viral loads 
were > 5 log10 copies/mL [29]. Neighbor-joining phylogenetics trees built from 
this study data revealed all known viral recombinant species from all four groups 
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(M, N, P, O), and rare M-subtypes (J and H). A successful strategy has been to 
study HIV species diversity by embedding a degenerate block of nucleotides, within 
the primer, during first round of cDNA synthesis, to avoid PCR-related errors (and 
sequencing errors [30, 31]. A unique ID (Primer ID), created by an incorporated 
primer tag, can correct allelic skewing during sequencing [32]. Using this approach 
the authors were able to identify minor variants in the HIV-1 protease gene resulting 
in multiple alleles that conferred drug-resistance [30].
The percentage of people living with HIV drug resistance appears to be increas-
ing [33]. RNA-seq has been key to revealing so-called viral invasive genes and the 
acquisition of drug-resistance mutations throughout of the 9.7 Kb of viral genome 
[34]. Achievement of long amplicon length allowed quantification of viral load and 
multiple drug-resistant mutations using viral RNA and pro-viral DNA as a template 
[35–38]. RNA-based long-read sequencing is also being explored for surveillance of 
viral diversification and assessment of HIV quasispecies [39, 40]. The FDA has cleared 
Sentosa HIV-1 RNA-Seq genotyping SQ assay for clinical use, to detect and monitor 
antiretroviral drug resistance mutations in the blood of HIV-infected patients. This 
product helps clinicians to prescribe effective combination of antiretroviral drugs, 
such as reverse transcriptase, integrase, envelope (gp41), or CCR5/CXCR4 inhibitors 
[39]. Phylogenetic clustering of genotyped samples from HIV patients who diagnosed 
between 1999 and 2012 identified strong associations between molecular clusters and 
epidemiological hotspots for transmitted drug resistance [41].
3. Sequencing of SARS-CoV-2
Viruses of the order Nidovirales - family Coronaviridae - subfamily 
Coronavirinae are positive-sense, single-stranded sequences of RNAs; ranging from 
26 to 32 kilobases in length [42]. The novel SARS-CoV-2 species was identified via 
metagenomic RNA sequencing and made publicly available, in NCBI Virus, within 
two months of unknown pneumonia cases outbreak in China (accession number 
NC_045512) [43]. The SARS-CoV-2 viral genome (made up of 29,903 nucleotides) 
is phylogenetically related to genus beta-coronavirus (subgenus sarbecovirus), 
which has demonstrated the ability to crossover, from the animal kingdom, and 
subsequently cause infection in humans [44]. A viral RNA genome encodes several 
structural proteins (spike, S; nucleocapsid, N; transmembrane, M; envelope, E). 
SARS-CoV-2 is known to produce 16 non-structural proteins, and at least six acces-
sory proteins (encoded primarily by reading frames ORF1 and ORF2) [45]. Each 
viral transcript has a 5′ cap structure and a 3′ poly(A) tail [46]. Genomic character-
ization of SARS-CoV-2 receptor-binding domains, in conjunction with phylogenetic 
analysis and homology modeling, revealed the sequence for viral port of entry 
proteins that conferred human-to-human transmission [47]. Direct RNA sequenc-
ing via nanopore and DNA nanoball methodologies identified that SARS-CoV-2 
generates a tiered series of canonical and non-canonical subgenomic RNAs, through 
a process involving homology recombinations between transcriptional regulatory 
sequences [48]. The function of these transcripts is currently unknown [49].
Sequencing-based genomic surveillance has been employed by UK, USA, and 
Canadian consortia, to coordinate efforts to sequence large numbers of SARS-CoV-2 
genomes. An executive summary “Genomic sequencing of SARS-CoV-2” was issued 
by the WHO, in January 2021. It discusses the implementation of NGS, for “maxi-
mum impact on public health” and provide detailed overview of current sequencing 
methodologies [50].
In lockstep with the continuing advances of next-generation sequencing tech-
nologies, the bioinformatics community has developed many computational tools 
5
Diagnostic Applications for RNA-Seq Technology and Transcriptome Analyses in Human…
DOI: http://dx.doi.org/10.5772/intechopen.99156
capable of keeping up with big data analysis and interpretation. Data sharing reposi-
tories such as GISAID (EpiCoV), NCBI Virus/GenBank, COG-UK, ENA provide free 
access to sequencing data (Figure 1). Bioinformatics workspaces (e.g., Terra [51], 
UshER [52], NextStrain [53, 54], PANGO Lineages [55], CoV-Glue [56], see Figure 1) 
allow users to assign their own sequences to globally circulating lineages [57].
Genomics researchers who track phylogenetic dynamics of SARS-CoV-2 devel-
oped several schemes to describe the accumulation of mutations and detectable 
divisions within circulating SARS-CoV-2 populations (Figure 2). Three popular 
clade naming conventions are used:
1. PANGO Lineages [55];
2. Clades by NextStrain [58];
3. Clades by GISAID [59].
The PANGO Lineages nomenclature refers to corresponding outbreaks caused 
by distinct lineages (Figure 2A). Lineage A is suggested to be ancestral because it 
shares more nucleotides similarities with related coronaviruses in animals [60]. 
Lineages B presumably originated from United Kingdom, and lineages P – from 
Brazil [61, 62]. The Clades by NextStrain and GISAID nomenclature refers to the 
divergence of newly emergent clades (see Figure 2B and C) [57, 59, 63]. A formal 
naming system for SARS-CoV-2 evolutionary lineages has not been universally 
adopted. The nomenclatures from PANGO Lineages and GISAID are updated 
on CDC and WHO web [64, 65]. Novel phylodynamic models for visualiza-
tion of phylogenomic datasets have been employed in different web formats. 
For example, Auspice, Augur, NextClade are open-source interactive web tools 
for visualizing phylogenomic data within NextStrain interface [66]. UShER 
(Ultrafast Sample placement on Existing tRee) is available in UCSC, and the virus 
phylogeny is a part of T-BioInfo platform [52]. Novel human coronavirus lineages 
are now regularly reported, and lineage nomenclature is continually updated 
[64]. The WHO Virus Evolution Working Group has been working on simplifying 
the nomenclature, for SARS-CoV-2 variants of interests (VOI) and variants of 
Figure 1. 
Diagnostic applications for RNA-Seq data analyses in human diseases caused by RNA viruses. The upper 
boxes represent bioinformatics workspaces for data analysis as described in the text below. The lower boxes 
represent major public repositories/databases commonly used for collecting and sharing genome sequence 
data (see abbreviations list). Note: Viral sequencing data are deposited in GISAID and NCBI virus; the 
ENA (EMBL-EBI), GEO, and SRA (NCBI) contain sequences from all domains of life, including human 
specimens). Double-headed arrows represent interactive nature between bioinformatics tools and data 
repositories, which allows for variants identification and gene expression assessment.
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concern (VOC). This group has recommended easy-to-pronounce variant nam-
ing based on the Greek alphabet (e.g. Alpha, Beta, Gamma, Delta - for VOC; and 
Epsilon thought Lambda – for VOI) [67].
Genomic epidemiology is a novel discipline that assesses viral genomic diversifi-
cation, including the acquisition of pathogenic mutations, and molecular dynamics 
Figure 2. 
Genomic epidemiology of novel severe acute respiratory syndrome coronavirus 2 (global subsampling). 2A. 
PANGO lineages. 2B. Clades by NextStrain. 2C. Clades by GISAID. These phylogenetic trees show time-
resolved visualization of evolutionary relationships between SARS-CoV-2 viruses from the ongoing COVID-19 
pandemic. Exported from https://nextstrain.org/ncov/global. The dots on the trees’ branches are color-coded in 
accordance with phylogeny classification by (2A) PANGO lineages; (2B) by NextStrain clades; (2C) clades by 
GISAID. Figure legends on the left represent lineages or clades names. Accessed on Apr 20th.
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of a pandemic, at the population level. Real-time viral sequencing helps delineate 
the origin of imported cases. For example, the assessment of WGS data (in sev-
eral European countries) enabled a more precise understanding of SARS-CoV-2 
transmission patterns, during various phases of the current pandemic. Molecular 
epidemiology data aided in identifying multiple introduction events, from the 
community spread in the Netherlands, Brazil, and several other countries [68–71]. 
WGS analysis leveraged with phylogenetic methodology approximated the source 
of lineage exportation. For example, the first outbreak of COVID-19 in Taiwan was 
imported from China. However, the second was from Italy, as strains that caused 
the second outbreak were phylogenetically more related to GISAID Accession IDs 
from the Italian outbreak [72]. As determined by the neighbor-joining method 
using MEGAX software, the circulating Moroccan lineage is more closely related 
to the South African lineage (20H/501Y.V2). This is not surprising given that travel 
within the continent is more predominant than travel between continents [73, 74]. 
In the United States, epidemiological investigation of sequencing data showed that 
SARS-CoV-2 varies at the single-nucleotide polymorphism (SNP) resolution, within 
various States. Additionally, SARS-CoV-2 genomic surveillance identified introduc-
tion and community spread of more transmissible strains in the states of California, 
Ohio, Washington and others (e.g., 20C > 20G clade switch) [75–79]. Genome 
sequencing in the New York City and Boston areas identified a cryptic spread of 
multiple simultaneous lineage introductions, from European or Asian travel-related 
exposures [80–82]. Using Global Epidemic and Mobility Model (GLEAM), Davis et 
al. estimated the time for the arrival and cryptic phase of the COVID-19 epidemic, 
which began in early to mid-January on both the East and West coasts of the USA 
[83]. During the cryptic phase of transmission, monophyletic clades of imported 
SARS-CoV-2 were spreading until air travel restrictions were dictated [83, 84].
US Center for Disease Controls and Prevention regularly updates the SARS-
CoV-2 variant classification, adding novel mutations that have an impact on the 
immune response or virus virulence factor. Variants are generally classified as a 
variant of interest, a variant of concern, and a variant of high consequence [64]. 
Genome-wide sequencing analysis of samples, from various geographic locations, 
has revealed novel mutations dispersed throughout SARS-CoV-2 genome [85]. 
Weber et.al has recently detected a number of hotspot mutations, juxtaposing SARS-
CoV-2 sequences from various geographic regions, which occurred de novo, during 
the dissemination of infection [60]. These differences in genome variation are not 
necessarily all pathogenic, but may be important in vaccine design and assessment 
of immunogenicity [86]. Molecular clock computations estimate that the average 
evolutionary rate for coronaviruses is roughly 10−4 nucleotide substitutions per site, 
per year, with point mutations that contribute to the diversification of global strains 
[87, 88]. Although most acquired genetic changes do not substantially affect viru-
lence or transmissibility, those that do cause the corresponding phenotypic changes 
in SARS-CoV-2 - are of public health importance [67, 85].
4. Advances in diagnostic sequencing methods
Diagnostic sequencing methods have reached a state of capability, which enables 
the detection of low quantities of viral RNA, with greater sensitivity and specificity. 
Several amplicon construction approaches have been utilized: targeted capture-
based, tiling hexamer-based, and standard amplicon-based [89–91]. A newly com-
mercialized methodology that includes the hybridization capture method yielded 
near-complete genome coverage, even in samples with relatively low viral loads 
(cycle thresholds, Ct > 25) [92]. Several studies reported that 93 to 99% of genome 
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coverage is the samples with Ct values ranging from 26 to 32. The median on-target 
percentage of genome coverage dropped below 50%, in higher Ct value samples 
(Ct > 30) [93]. Public Health Laboratories have recently utilized capture-based 
methods followed by sequencing to evaluate if SARS-CoV-2 is present in wastewater 
samples. The goal of the study was the detection the meta-transcriptomic differ-
ences between SARS-CoV-2 variants, found in wastewater, and compare the differ-
ences to locally reported clinical genotypes [77]. An Illumina Flex for Enrichment 
kit and Illumina Respiratory Virus Oligo Panel were used to enrich the samples for 
virus cDNA amplicon.
The tiling amplicon-based approach has been adapted for SARS-CoV-2 sequenc-
ing. It is based on modified reverse transcription (RT with designed primer pool) and 
an overlapping long amplicon multiplex PCR strategy [94]. Primers can be designed 
in a random-hexamer-primed RT fashion, and a not-so-random-hexamer-primed 
fashion, to eliminate human rRNA during cDNA synthesis. The number of prim-
ers can reach up to 400, in metagenomics protocols, to improve genome coverage. 
However, less than 20 primers are used more widely for amplicon construction 
[95–97]. The tiling amplicon-based approach has been validated by many laboratories 
and adapted for nanopore sequencing technologies as well as Illumina and Sanger 
sequencing [97–99]. A Swift Biosciences’ Normalase® tiling amplicon SARS-CoV-2 
panel achieved 80% success of partial genome recovery from samples with a Ct value 
between 32 and 34, and 40% - for samples with a Ct value between 34 and 36 [100]. 
A 98 non-overlapping primer pair set have been designed by a group of scientists 
from ARTIC network in early March of 2020. This primer set has been modified on 
3 occasions, reducing primer-dimers formation during RT-PCR (a major cause of 
coverage bias) [101]. Recently, the ARTIC’s CoronaHiT platform (Coronavirus High 
Throughput) has been launched and provided accurate consensus SARS-CoV-2 
genomes when at least 20x coverage is obtained. It is important to note that in the 
low-titer samples, with Ct > 32 (< 100 viral genome copies/uL), sequencing results 
became less reliable for all sequencing methods (long- and short- read) [96, 102–104].
5. Assessment of host response by RNA-Seq
The host-pathogen interactions have been studied by RNA-Seq in research  
settings. Transcriptome analysis of hosts’ diseased tissues has been an integral part 
of the discovery of immune response biomarkers. University of Minnesota Division 
of Infectious Diseases (USA) leads intensive transcriptomic studies for discoveries of 
novel biomarkers of immune reconstitution inflammatory syndrome (IRIS) in the 
HIV-infected population [105, 106]. IRIS presents as an exaggerated immune reaction 
(in a form of cytokine release syndrome) that occurs in immunocompromised patients 
who have commenced antiretroviral treatments (ART) [106]. Several predictive and 
diagnostic biomarkers have already been identified in peripheral blood, utilizing 
Galaxy, JMP Genomics, or Partek Flow software (Figure 1). For example, the low 
expression of type I interferon, interferon-response genes, and components of antivi-
ral defense pathways were identified as a risk factor for subsequent occurrence of non-
fatal forms of IRIS [107, 108]. More recently, transcriptomic predictors of fatal IRIS 
have been delineated. These include the overexpressed genes that encode numerous 
proinflammatory cytokines (e.g., IL6), chemokines, stress response kinase signaling 
and production of reactive oxygen species in monocytes pathways [109]. Interestingly, 
the deficiency in innate antiviral defense genes, and poly-immuno-cytopenia have also 
been identified as significant contributors to subsequent cytokine release syndrome 
during COVID-19 [110–112]. The reduced IFN I and IFN III type gene expression 
and elevated monocyte- and granulocyte- derived chemokines at an early stage of 
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COVID-19 have been proposed as predictors of subsequent cytokine release syndrome 
and disease severity [113].
In a small percentage of the human population, the SARS-CoV-2 infection 
results in a critical illness that begins with uncontrolled overexpression of proin-
flammatory cytokines (the so-called “cytokine storm”) [114]. A cytokine storm 
may lead to pathophysiological events such as activation of the coagulation cas-
cades, systemic oxidative stress, and various forms of cell death [115]. Clinically, 
these events manifest as an acute respiratory distress syndrome (ARDS), or 
death from multiple organ failure [116, 117]. SARS-CoV-2 is recognized by innate 
immune cells and, in cases of ARDS, elicits highly abundant transcriptional gene 
expression, which is somewhat comparable to that of immunocompromised 
patients who have developed fatal IRIS [109, 118, 119]. The upregulation of 
inflammasome, Toll-like receptor signaling, HMGB1, and oxidative stress response 
transcripts, have been recently demonstrated as biomarkers of fatal immune 
reconstitution inflammatory syndrome [109]. Additionally, NF-kB-associated 
inflammatory genes and strong neutrophile activation/degranulation signatures 
differentiate fatal IRIS events from those of survivors. Likewise, fatal ARDS in 
COVID-19 patients have been characterized by maladapted hyperactivation of the 
same innate inflammatory pathways described for fatal IRIS [120–123]. Systemic 
upregulation of cytokines TNFa, IL6, IL1B, and NLRP3 are noteworthy of men-
tion as they are targetable molecules for drugs such as adalimumab, tocilizumab, 
anakinra, and RAPA-501-Allo, respectively [124–127].
SARS-CoV-2 has the propensity to selectively induce mortality in elderly popula-
tion (over 65 years of age) and in immunocompromised individuals [128, 129]. 
The most reasonable explanation for this propensity is the depletion of the thymic 
population, and the inability to mount adaptive T cell immune responses in timely 
manner [130]. Innate immune cells become the first line of defense against SARS-
CoV-2, however in the absence of proper regulatory feedback – are thrown into an 
uncontrolled proinflammatory loop. Similarly, the irreparable thymic damage and 
a waning adaptive immunity in AIDS patients enable the sustained HIV replica-
tion, which may explain why serious complications such as fatal IRIS are hinged on 
responses driven by innate immune cells.
There have been isolated cases of SARS-CoV-2 reinfection in individuals who 
had no known immune disorders [131–133]. Since SARS-CoV-2 has not diversified 
significantly, these patients have been re-infected with variants from the same or 
adjacent clade [132]. Studies have revealed a number of SARS-CoV-2 epitopes are 
recognized by CD8+ T cells in COVID-19 convalescent subjects (as determined by 
TruSight HLA sequencing panel) [134]. It is hypothesized that re-infected individu-
als are unable to mount a sufficient response to primary infection, which result in 
secondary COVID-19 manifestation. Many of these patients had tested positive for 
anti- SARS-CoV-2 antibodies after the reinfection, but it is unknown whether they 
developed antibodies after the first infection at all. It has been hypothesized that 
susceptibility to re-infection is genetically driven [135]. Several hypothetical models 
had been proposed [136]. Thus, simultaneous RNA-seq of host and pathogen during 
viral infection would be helpful to characterize the molecular responses in case of 
COVID-19 reinfection.
There are now several vaccine types that are being used, in an attempt to reach 
herd immunity, in various countries [137]. The most successful vaccines are mRNA-
based, which have an estimated 92% efficacy [138, 139]. Still, there is an accu-
mulating body of evidence of the so-called ‘vaccine breakthrough’ phenomenon, 
when SARS-CoV-2 infection occurs in persons who are fully vaccinated [140, 141]. 
The immune gene variants that contribute to poor T cell memory and undelaying 
vaccine breakthroughs are not yet known [142]. As vaccination increases, RNA-Seq 
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may become a useful tool in exploring the consequence of vaccine dose-spearing 
strategies, the emergence of novel vaccine-escape variants, intra- host variant 
diversity, as well as in understanding the phenomenon of vaccine breakthrough.
6. Conclusion and future directions
RNA-seq has become an indispensable diagnostic tool of clinically important 
RNA viruses. It has taken the research community almost 20 years to sequence a 
complete HIV viral genome, but it took a little over 2 months to sequence a near 
complete SARS-CoV-2 genome and identify its origin! With an improved under-
standing of the genomic structures of virus populations, RNA-seq can be used to 
track the origins, genetic diversity, and global monitoring of transmission pat-
terns. In a public health context, RNA-Seq is an indispensable tool to be utilized 
in the assessment of risks and the emergence of future outbreaks. Additionally, 
assessment of transcriptomic profiles, during host responses to infection improved 
the understanding of disease pathogenesis and identify patients at risk for severe 
outcomes. To overcome drug resistance, novel viral genotype-guided agents based 
on antisense RNAs (e.g., aptamers, peptide nucleic acids oligomers, ribozymes, and 
RNAi silencing therapies) are being developed to specifically inhibit viral replica-
tion. Complex bioinformatics approaches enabled vaccines to be designed with high 
probabilities of intercepting viral escape [143]. Much work awaits the global scien-
tific community, including the establishment of unified reference standards and the 
adoption of a single nomenclature for SARS-CoV-2. Additionally, the assessment of 
long-term vaccination efficacy by RNA-Seq in the clinical laboratory is necessary to 
fully understand its benefits [144].
Abbreviations
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
CDC Center for Disease Controls and Prevention
UCSC University of California, Santa Cruz
GISAID Global Initiative on Sharing Avian Flu Data
ENA European Nucleotide Archive
COG-UK COVID-19 Genomics UK Consortium
WGS whole genome sequencing
SNP single-nucleotide polymorphism
NCBI The National Center for Biotechnology Information
UShER Ultrafast Sample placement on Existing tRee
IRIS immune reconstitution inflammatory syndrome
TNFA Tumor Necrosis Factor Alfa
HMGB1 High Mobility Group Box 1 gene
NLRP3 NLR (nucleotide-binding domain and leucine-rich repeat contain-
ing) Family Pyrin Domain Containing 3
EMBL-EBI European Molecular Biology Laboratory - European Bioinformatics 
Institute
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